Cancers, Vol. 16, Pages 1516: Proteomic Analysis of Spatial Heterogeneity Identifies HMGB2 as Putative Biomarker of Tumor Progression in Adult-Type Diffuse Astrocytomas

Cancers, Vol. 16, Pages 1516: Proteomic Analysis of Spatial Heterogeneity Identifies HMGB2 as Putative Biomarker of Tumor Progression in Adult-Type Diffuse Astrocytomas Cancers doi: 10.3390/cancers16081516 Authors: Aline P. Becker Valesio Becker Joseph McElroy Amy Webb Chunhua Han Yingshi Guo Erica H. Bell Jessica Fleming Ilinca Popp Ori Staszewski Marco Prinz Jose J. Otero Saikh Jaharul Haque Anca-Ligia Grosu Arnab Chakravarti Although grading is defined by the highest histological grade observed in a glioma, most high-grade gliomas retain areas with histology reminiscent of their low-grade counterparts. We sought to achieve the following: (i) identify proteins and molecular pathways involved in glioma evolution; and (ii) validate the high mobility group protein B2 (HMGB2) as a key player in tumor progression and as a prognostic/predictive biomarker for diffuse astrocytomas. We performed liquid chromatography tandem mass spectrometry (LC-MS/MS) in multiple areas of adult-type astrocytomas and validated our finding in multiplatform-omics studies and high-throughput IHC analysis. LC-MS/MSdetected proteomic signatures characterizing glioma evolution towards higher grades associated with, but not completely dependent, on IDH status. Spatial heterogeneity of diffuse astrocytomas was associated with dysregulation of specific molecular pathways, and HMGB2 was identified as a putative driver of tumor progression, and an early marker of worse overa...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research